Topic summary

Research-use-only labelling: what it means and what it does not — the long version

Sourcing › Regulatory EMA research use only compounding

This is a generated summary. It shows the 9 most-liked posts from a topic of 159, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

KForsbergTL2Member26 Sep 2024#4

Off-label use and medical practice: clinicians can prescribe approved medications off-label under some circumstances. That is different from research-use-only compounds, which are not approved for any human use.

31 likes 22mo

r.aldana_pharmdTL4Pharmacist13 Nov 2024#26

I read post #24 twice before replying, because I had assumed the opposite.

Preclinical versus clinical: compounds with strong preclinical data can fail in clinical trials. Compounds with no human data are being used on theoretical grounds. The regulatory position reflects this asymmetry.

28 likes 20mo

stopper_traceTL2Member16 Dec 2024#45

Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.

29 likes 19mo

TavaresTL1Member7 Jan 2025 · edited#59

Why this category is maintained as documentation, not as recommendations: the goal is factual accuracy and sourcing, not endorsement of any specific regulatory position.

28 likes 19mo

orbitrap_olaTL3Mass spectrometrist20 Feb 2025#89

b.wikstrom, post #88: Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold. Go to post

Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable.

32 likes in reply to #88 17mo

a.amankwahTL2 Moderator18 Mar 2025#108

Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is tedious but necessary.

29 likes 16mo

h.oyelowoTL2Regular20 Mar 2025#109

On post #105 — agreed on the reasoning, with one qualification.

27 likes 16mo

a.ibarraTL2 Moderator29 Mar 2025#116

I read post #114 twice before replying, because I had assumed the opposite.

Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The label does not establish whether the molecule is safe, efficacious, or toxic.

30 likes 16mo

ne.laurentTL2 Moderator4 Apr 2025#121

priorauth_notes, post #31: On post #27 — agreed on the reasoning, with one qualification. Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable. Go to post

Coming back to post #119, because the follow-up matters more than the original answer.

31 likes in reply to #31 16mo

Read the full topic (159 posts)

Moved from Independent verification by bench_notes. Category placement is not obvious from outside and getting it wrong is expected. This topic will get better answers here. The move is recorded in the public log citing R7.

Suggested topics

Topic	Participants	Replies	Views	Activity
Enforcement priorities versus written rules — does this still hold? Sourcing › Regulatory EMA MHRA compounding FDA Solved Under review Enforcement priorities versus written rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Structured report rather than an opinion, following…	+36	40	37k	11mo
Second pass at: Import rules for personal quantities, by jurisdiction, dated Sourcing › Regulatory research use only personal import FDA MHRA Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are…		2	5k	11mo
Research-use-only labelling: what it means and what it does not Sourcing › Regulatory compounding research use only EMA FDA Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. I would like to talk about documentation quality as a…	+100	110	37k	5mo
Prescription requirements and telehealth models — a second dataset Sourcing › Regulatory compounding EMA MHRA personal import On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…	+87	94	1.1k	21d
Enforcement priorities versus written rules Sourcing › Regulatory FDA personal import MHRA Enforcement priorities versus written rules — setting out what I have, and where I think it stops being reliable. I would like to talk about documentation quality as a signal, separately from product quality.…		2	62k	15mo

Related topics — sharing the tags EMA, research use only, compounding

Topic	Participants	Replies	Views	Activity
Pen wastage and its effect on real cost — the long version Access › Pricing formulary data table cost per milligram compounding Posting this under the heading it deserves: Pen wastage and its effect on real cost — the long version Everything below is what sits behind that. Documenting an access outcome, dated, because everything in…		2	34k	13mo
Second pass at: How to research a compound with no human data without deceiving yourself Compounds › Other compounds research use only custom synthesis needs a source mislabelling Second pass at: How to research a compound with no human data without deceiving yourself Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med ,…	+64	71	2.5k	13mo
EU-wide position versus national implementation Regional › European Union EMA personal import cost per milligram formulary Solved Under review EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category…	+22	29	356	11mo
Coming back to: Payment method and the leverage it gives you, ranked Sourcing › Payments payments documentation quality research use only Payment method and the leverage it gives you, ranked — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the maintainers asked…	+21	26	43k	2d
Second pass at: Hoarding and why it makes a shortage worse Access › Shortages FDA compounding shortage Second pass at: Hoarding and why it makes a shortage worse Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this…	+115	133	11k	21mo